INDICATION AND USAGE

COLORECTAL CANCER
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with Fluoropyrimidine-, Oxaliplatin- and Irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wildtype, an anti-EGFR therapy.

GASTROINTESTINAL STROMAL TUMORS
Regorafenib is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with Imatinib mesylate and Sunitinib malate.

HEPATOCELLULAR CARCINOMA
Regorafenib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib.